Objectives: Treatment of chronic lymphocytic leukemia (CLL) is currently undergoing dramatic changes. We analyzed economic risks in hospitalized patients with CLL from a management perspective. Methods: One hundred and twelve patients with CLL hospitalized in 2013 and 2014 at the University Hospital of Cologne were analyzed. To assess profit margins (PMs) per case, diagnosis-related group (DRG) reimbursement data were merged with an internal cost accounting scheme depending on age, prognostic factors, and DRG key performance indicators. Results: In 112 patients, 284 cases coded by 19 different DRG with strongly fluctuating cost revenue ratios were found with an overall negative PM of (sic)137 147. The DRG R61H was identified as the one most...
Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating ...
textabstractThe aim of this study was to assess the cost-effectiveness, from a health care perspecti...
Chronic diseases have become the most common health problems worldwide. The cost of chronic disease ...
Class of 2012 AbstractSpecific Aims: The objectives of this study were to determine the financial im...
We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chro...
No recent full-text-based systematic review has been published to examine economic evidence around a...
In this article, we carry out an overview on the management options available for chronic lymphocyti...
textabstractDuring the last decade the management of CLL was subject to progressive changes in diagn...
Purpose Oral targeted therapies represent a significant advance for the treatment of patients with c...
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the Weste...
AbstractObjectiveThe aim of this study was to identify, from a health care perspective, the cost of ...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
The survival and other disease quality indicators of Chronic Myeloid Leukemia (CML) have been largel...
Background. Currently, treatment of recurrent / refractory chronic lymphocytic leukemia (CLL) involv...
Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating ...
textabstractThe aim of this study was to assess the cost-effectiveness, from a health care perspecti...
Chronic diseases have become the most common health problems worldwide. The cost of chronic disease ...
Class of 2012 AbstractSpecific Aims: The objectives of this study were to determine the financial im...
We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chro...
No recent full-text-based systematic review has been published to examine economic evidence around a...
In this article, we carry out an overview on the management options available for chronic lymphocyti...
textabstractDuring the last decade the management of CLL was subject to progressive changes in diagn...
Purpose Oral targeted therapies represent a significant advance for the treatment of patients with c...
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the Weste...
AbstractObjectiveThe aim of this study was to identify, from a health care perspective, the cost of ...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chro...
The survival and other disease quality indicators of Chronic Myeloid Leukemia (CML) have been largel...
Background. Currently, treatment of recurrent / refractory chronic lymphocytic leukemia (CLL) involv...
Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating ...
textabstractThe aim of this study was to assess the cost-effectiveness, from a health care perspecti...
Chronic diseases have become the most common health problems worldwide. The cost of chronic disease ...